All In Biotech

Drug Trial Radar · NCT04551911

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)

Last checked: Nov 19, 2026Latest source record: May 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 171 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

171

Actual

Start

Nov 2, 2020

Primary completion

Oct 8, 2021

Study completion Oct 8, 2021

Sponsor

Lead sponsor
OPKO Health, Inc.Industry
Sponsor type
Industry
First posted
Sep 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.

Conditions

  • COVID-19
  • Coronavirus
  • SARS-CoV2 Infection

Interventions

  • RayaldeeDrug

    30 mcg calcifediol Extended-Release (ER) Capsule

  • PlaceboDrug

    0 mcg calcifediol Extended-Release (ER) Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).Time frame: 14 days
  2. Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.Time frame: 42 days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • OPKO Investigative Site

    San Francisco, California

  • OPKO Investigative Site

    Miami, Florida

  • OPKO Investigative Site

    Miami, Florida

  • OPKO Investigative Site

    Evanston, Illinois

  • OPKO Investigative Site

    Laurel, Maryland

  • OPKO Investigative Site

    Farmington Hills, Michigan

  • OPKO Investigative Site

    Jackson, Michigan

  • OPKO Investigative Site

    Sterling Heights, Michigan

  • OPKO Investigative Site

    Brookhaven, Mississippi

  • OPKO Investigative Site

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.